#CHIR99021 ; #2520691 ; *** BioGems 제품이나 Peprotech 으로 표기
Regen Med. 2024 Jan;19(1):47-63.
Aldyn Wildey 1, Stephen Harrington 1, Lisa Stehno-Bittel 1 2, Francis Karanu 1
Affiliations expand
- PMID: 38240144
- DOI: 10.2217/rme-2023-0187
Abstract
Aim: Cell therapies for diabetes rely on differentiation of stem cells into insulin-producing cells, which is complex and expensive. Our goal was to evaluate production costs and test ways to reduce it. Methods: Cost of Goods (COGs) analysis for differentiation was completed and the effects of replacement or reduction of the most expensive item was tested using qRT-PCR, immunohistochemistry, flow cytometry along with glucose-stimulated insulin release. Results: Activin A (AA) was responsible for significant cost. Replacement with small molecules failed to form definitive endoderm (DE). Reducing AA by 50% did not negatively affect expression of beta cell markers. Conclusion: Reduction of AA concentration is feasible without adversely affecting DE and islet-like cell differentiation, leading to significant cost savings in manufacturing.
Keywords: Activin A; cost of goods analysis; differentiation; human induced pluripotent stem cells; islet-like cells.